Your session is about to expire
← Back to Search
Selinexor for Non-Small Cell Lung Cancer
Study Summary
This trial is testing selinexor as a possible treatment for KRAS mutant lung cancer in patients who have already tried other treatments.
- Non-Small Cell Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 116 Patients • NCT02025985Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this medical study currently enrolling new participants?
"As per clinicaltrials.gov, this investigation is no longer open for recruitment. First posted in March 2018 and last updated November 2022, the trial has closed its doors to new applicants; however 2315 other experiments are currently enrolling patients right now."
Have any other investigations explored the potential of Selinexor?
"At the moment, Selinexor has 366 studies underway with 130 trials in Phase 3. While Saint Louis is a hub for research on this drug, there are 23292 centres worldwide that have running investigations of Selinexor."
What maladies is Selinexor employed to combat?
"Selinexor is regularly used to treat cancerous tumours, and in some cases it can be prescribed to manage specific conditions such as sarcoma, refractory multiple myeloma, or advanced directives."
How many individuals have been recruited to participate in this experiment?
"Unfortunately, recruitment for this trial has been suspended. It was first advertised on March 22nd 2018 and the last update took place November 15th 2022. Those seeking alternative clinical trials can look into 1949 studies recruiting patients with carcinoma non-small cell lung cancer or 366 studies that require participants to take Selinexor."
In what geographic locations is this clinical research initiative being conducted?
"This particular medical trial is recruiting from University of Washington-Seattle Cancer Care Alliance in Seattle, the University of Pittsburgh Medical Center-Hillman Cancer Centre in Pennsylvania, and University of Texas Southwestern Medical Centre in Dallas. Additionally, there are 5 additional sites taking part."
Share this study with friends
Copy Link
Messenger